Bortezomib
Small molecule targets MGMT, TGFB1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 15 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | BORTEZOMIB | — | 2021-09-20 – 2022-12-09 | fda.gov ↗ |
| Label expansions (11) | US (FDA) | VELCADE | — | 2005-03-25 – 2019-04-25 | fda.gov ↗ |
| Approved | EU (EMA) | Velcade | — | 2004-04-26 | europa.eu ↗ |
| Approved | US (FDA) | VELCADE | — | 2003-05-13 | fda.gov ↗ |
Trials 744 · started per year
Also used as a comparator or background therapy in 215 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04776850 Background | Dec 2020 → Dec 2022 | beta-thalassemia major, sickle cell disease, sickle cell-beta plus-thalassemia, sickle cell-beta zero-thalassemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT01537861 Background | Jun 2012 → Feb 2014 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 131 trials | ||||||
| Phase 1 | NCT07609706 Background | Oct 2026 → Aug 2031 expected | plasma cell myeloma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05052970 Background | Oct 2021 → Apr 2023 | refractory plasma cell neoplasm | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04956302 Background | Sep 2021 → Jun 2022 | plasma cell myeloma | Abdullah Khan | Terminated | No outcome recorded |
| Phase 1 | NCT04996160 Background | Jul 2021 → Oct 2023 | childhood acute lymphoblastic leukemia | Tanja Andrea Gruber | Completed | No outcome recorded |
| Phase 1 | NCT04722146 Background | Mar 2021 → Oct 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04570631 Background | Nov 2020 → May 2025 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT04091126 Background | Dec 2019 → Jun 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03984097 Background | Jul 2019 → Mar 2026 | plasma cell myeloma | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03515200 Background | Apr 2018 → Jul 2020 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT02613598 Background | May 2016 → Jun 2021 | Hodgkins lymphoma, non-Hodgkin lymphoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02497378 Background | Jul 2015 → Mar 2018 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT01998971 Background | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01965353 Background | Oct 2013 → Mar 2019 | plasma cell myeloma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02481934 Background | Mar 2013 → Jul 2016 | plasma cell myeloma | Joaquín Martínez López, MD, PhD | Completed | No outcome recorded |
| Phase 1 | NCT01680796 Background | Feb 2013 | plasma cell myeloma | University of Florida | Withdrawn | No outcome recorded |
| Phase 1 | NCT01794507 Background | Nov 2012 → Jul 2019 | refractory plasma cell neoplasm | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01485835 Background | Jan 2012 → Sep 2015 | plasma cell myeloma | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01495351 Background | Oct 2011 → Feb 2015 | plasma cell myeloma | AHS Cancer Control Alberta | Completed | No outcome recorded |
| Phase 1 | NCT01464112 Background | Sep 2011 → Nov 2013 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01359657 Background | Sep 2011 → Mar 2016 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01504776 Background | Apr 2011 → Sep 2014 | mantle cell lymphoma | Anand Jillella | Completed | No outcome recorded |
| Phase 1 | NCT01248923 Background | Dec 2010 → Mar 2016 | plasma cell neoplasm | Array BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT01164709 Background | Jul 2010 → Jul 2012 | leukemia, neoplasm of mature T-cells or NK-cells, plasma cell neoplasm | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00884546 Comparator | Jul 2009 → Mar 2012 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00720785 Background | Aug 2008 → Apr 2021 | chronic myeloid leukemia, colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1 | NCT00538187 Background | Dec 2007 → Apr 2011 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT01233895 Background | Sep 2006 → Sep 2008 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00310024 Background | Nov 2005 → Feb 2008 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00258245 Background | May 2005 → Apr 2008 | plasma cell myeloma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00083460 Comparator | Dec 2001 → Nov 2007 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 1 | NCT02658396 Background | ? → May 2019 | plasma cell myeloma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1/234 trials | ||||||
| Phase 1/2 | NCT07600151 Background | Dec 2026 → Sep 2036 expected | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07099391 Background | Jul 2025 → Jul 2029 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05848687 Background | Nov 2023 → Dec 2028 expected | acute lymphoblastic leukemia | Tanja Andrea Gruber | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06087653 Background | Oct 2023 → May 2026 overdue | plasma cell myeloma | Starton Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05470491 Background | Jan 2023 → Jul 2026 overdue | HIV infectious disease, hematopoietic and lymphoid cell neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05514990 Background | Oct 2022 → Dec 2026 expected | plasma cell myeloma | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05392946 Background | Aug 2022 → Sep 2026 expected | plasma cell myeloma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04445701 Background | Nov 2020 → Aug 2022 | plasma cell myeloma | Arch Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT03989414 Background | Sep 2019 → Nov 2026 expected | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04068597 Background | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04025450 Background | Jul 2019 → Jul 2029 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03701321 Background | Jan 2019 → May 2020 | plasma cell myeloma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03607643 Background | Jan 2019 → Jun 2020 | colon carcinoma, gallbladder cancer, glioblastoma, liver cancer +3 | Leaf Vertical Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03544281 Background | Sep 2018 → Feb 2023 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT03136653 Background | May 2017 → Oct 2020 | plasma cell myeloma | Molecular Partners AG | Completed | No outcome recorded |
| Phase 1/2 | NCT02928029 Background | Feb 2017 → Mar 2019 | plasma cell myeloma | Bayer | Terminated | No outcome recorded |
| Phase 1/2 | NCT02605356 Background | Oct 2016 → Nov 2019 | plasma cell myeloma | Bayer | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02500251 Background | Jun 2015 → Jun 2018 | transplant rejection | E. Steve Woodle | Completed | No outcome recorded |
| Phase 1/2 | NCT02265510 Background | Sep 2014 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT01827137 Background | Apr 2013 → Dec 2016 | plasma cell myeloma | Sellas Life Sciences Group | Completed | No outcome recorded |
| Phase 1/2 | NCT01668719 Background | Nov 2012 → Feb 2020 | plasma cell myeloma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 1/2 | NCT01672736 Background | Sep 2012 → Mar 2017 | plasma cell myeloma | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 1/2 | NCT01531998 Background | May 2012 → May 2014 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01860170 Comparator | Apr 2012 → Mar 2016 | hematopoietic and lymphoid cell neoplasm | Corewell Health West | Completed | No outcome recorded |
| Phase 1/2 | NCT01394354 Background | Aug 2011 → Dec 2015 | plasma cell myeloma | University Hospital Freiburg | Completed | No outcome recorded |
| Phase 1/2 | NCT01381692 Background | Jul 2011 → Dec 2014 | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01255527 Comparator | Oct 2010 → Dec 2014 | — | Yonsei University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01242267 Background | May 2010 → Jan 2016 | plasma cell myeloma | Hackensack Meridian Health | Completed | No outcome recorded |
| Phase 1/2 | NCT00920855 Background | Jun 2009 → Jul 2011 | plasma cell myeloma | Cephalon | Completed | No outcome recorded |
| Phase 1/2 | NCT00507442 Background | Aug 2007 → Oct 2010 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00431990 Background | Nov 2006 → Dec 2011 | plasma cell myeloma | Peter MacCallum Cancer Centre, Australia | Unknown | No outcome recorded |
| Phase 1/2 | NCT00352742 Background | Jun 2006 → Sep 2008 | plasma cell myeloma | Attenuon | Terminated | No outcome recorded |
| Phase 1/2 | NCT00469209 Comparator | Jun 2006 → Dec 2008 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00793650 Comparator | May 2005 → Oct 2009 | plasma cell myeloma | Emory University | Terminated | No outcome recorded |
| Phase 257 trials | ||||||
| Phase 2 | NCT07614360 Background | Aug 2026 → Feb 2029 expected | plasma cell myeloma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07247097 Background | Aug 2026 → Dec 2030 expected | plasma cell myeloma | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07224672 Background | Jun 2026 → Jan 2033 expected | AL amyloidosis | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT07464210 Background | Jun 2026 → Aug 2029 expected | Waldenstrom macroglobulinemia | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07149857 Background | Oct 2025 → Apr 2028 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT07045909 Background | Jun 2025 → Mar 2028 expected | plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT06648889 Background | Oct 2024 → Feb 2028 expected | T-cell acute lymphoblastic leukemia | Goethe University | Recruiting | No outcome recorded |
| Phase 2 | NCT06577025 Background | Aug 2024 → Sep 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06169215 Background | Jul 2024 → Sep 2026 expected | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06353022 Background | Jun 2024 → Apr 2028 expected | plasma cell myeloma | Nantes University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05231629 Background | Dec 2023 → Dec 2027 expected | plasma cell myeloma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT04915248 Background | Jul 2022 → Jul 2027 expected | plasmablastic lymphoma | Fondazione Italiana Linfomi - ETS | Recruiting | No outcome recorded |
| Phase 2 | NCT04240054 Background | Nov 2021 → Dec 2029 expected | plasma cell myeloma | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 2 | NCT04717700 Background | Aug 2021 → Aug 2025 overdue | plasma cell myeloma | Ida Bruun Kristensen | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04626791 Background | Aug 2021 → Aug 2024 overdue | mantle cell lymphoma | Academic and Community Cancer Research United | Recruiting | No outcome recorded |
| Phase 2 | NCT04653246 Background | Jul 2021 → Dec 2025 overdue | plasma cell myeloma | Jacob Laubach, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04474938 Background | May 2021 → Jun 2023 | AL amyloidosis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04802356 Background | Apr 2021 → Mar 2025 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04304144 Background | Mar 2020 → Nov 2023 | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04133636 Background | Nov 2019 → Feb 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03004287 Background | Jul 2017 → Oct 2026 expected | plasma cell myeloma | University of Arkansas | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03117361 Background | May 2017 → Jul 2018 | plasma cell myeloma | PharmaMar | Terminated | No outcome recorded |
| Phase 2 | NCT03000634 Background | Apr 2017 | plasma cell myeloma | University of Arkansas | Withdrawn | No outcome recorded |
| Phase 2 | NCT02951819 Background | Nov 2016 → Mar 2018 | plasma cell myeloma | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02902965 Background | Sep 2016 → Oct 2018 | plasma cell myeloma | Pharmacyclics Switzerland GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02719613 Background | Jul 2016 → Feb 2026 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02720510 Comparator | Jun 2016 → May 2017 | plasma cell myeloma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02370693 Comparator | Mar 2016 → Dec 2019 | interstitial lung disease, systemic sclerosis | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT02440464 Background | Aug 2015 → Oct 2020 | plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT02573935 Background | Jan 2015 → Sep 2016 | plasma cell myeloma | Henrik Gregersen | Terminated | No outcome recorded |
| Phase 2 | NCT02254551 Background | Jan → Oct 2015 | plasma cell myeloma | SCRI Development Innovations, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02188537 Background | Dec 2014 → Jul 2016 | plasma cell myeloma | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT02424851 Comparator | Nov 2014 → Apr 2020 | chronic kidney disease, plasma cell myeloma | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT02188368 Background | Jul 2014 → Oct 2020 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02057380 Background | Apr 2014 → Oct 2016 | cancer | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01873157 Comparator | Dec 2013 → Feb 2015 | transplant rejection | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT01706666 Background | Dec 2012 → Jul 2014 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01602224 Background | Jul 2012 → Jul 2014 | plasma cell myeloma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01492881 Background | Apr 2012 → Jan 2015 | plasma cell myeloma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT01337752 Background | Jan 2012 → May 2013 | impaired renal function disease, plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01329289 Background | Dec 2011 → Feb 2012 | plasma cell myeloma | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 2 | NCT01478048 Background | Nov 2011 → May 2014 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01237249 Comparator | Feb 2011 → Aug 2014 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 2 | NCT01215344 Background | Nov 2010 → Nov 2015 | plasma cell myeloma | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01190787 Background | Jul 2010 → May 2012 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 2 | NCT01083602 Background | Jun 2010 → Feb 2014 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00911859 Comparator | Jun 2009 → Apr 2013 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00871546 Comparator | Mar 2009 → Dec 2010 | B-cell chronic lymphocytic leukemia, mantle cell lymphoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00706953 Comparator | Jul 2008 → Jun 2010 | plasma cell myeloma | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00722722 Comparator | Jun 2008 → Apr 2014 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00531453 Background | Oct 2007 → Apr 2009 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00473590 Background | Jun 2007 → Nov 2009 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00401843 Background | Nov 2006 → Aug 2011 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01370434 Comparator | Jul 2006 → Jan 2009 | plasma cell myeloma | Cooperative Study Group A for Hematology | Completed | No outcome recorded |
| Phase 2 | NCT00095680 Comparator | Nov 2004 → Feb 2006 | plasma cell myeloma | Scios, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00092222 Comparator | Oct 2004 → Oct 2026 expected | HIV infectious disease, cancer, human herpesvirus 8 infection, lymphoproliferative syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00087867 Background | Jun 2004 → Sep 2005 | plasma cell myeloma | Scios, Inc. | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07072585 Background | Aug 2026 → Sep 2035 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Children's Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05063513 Background | Jul 2009 → Jul 2013 | systemic lupus erythematosus | European Society for Blood and Marrow Transplantation | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00514371 Background | Aug 2007 → Feb 2009 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 376 trials | ||||||
| Phase 3 | NCT07709715 Comparator | Jan 2027 → Dec 2028 expected | AL amyloidosis | Nexcella Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07665450 Comparator | Sep 2026 → Sep 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07285239 Background | Jul 2026 → Nov 2031 expected | plasma cell myeloma | PrECOG, LLC. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07671287 Comparator | Jun 2026 → Feb 2031 expected | plasma cell myeloma | University of Heidelberg Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07623798 Comparator | Jun 2026 → May 2029 expected | refractory plasma cell neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07391657 Comparator | Feb 2026 → Jun 2028 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07579234 Comparator | Jan 2026 → Jan 2029 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 3 | NCT07388602 Background | Jan 2026 → Dec 2027 expected | amyloidosis | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07297329 Background | Dec 2025 → Dec 2027 expected | plasma cell myeloma | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06413498 Comparator | Aug 2024 → Jul 2028 expected | plasma cell myeloma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06022939 Background | Jul 2024 → Jul 2030 expected | AL amyloidosis | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT06464991 Comparator | Mar 2024 → Aug 2027 expected | plasma cell myeloma | Nanjing IASO Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06152575 Comparator | Feb 2024 → Aug 2026 overdue | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06208150 Comparator | Jan 2024 → Apr 2026 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05561387 Comparator | Oct 2023 → May 2031 expected | plasma cell myeloma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT05257083 Background | Oct 2023 → Jun 2033 expected | plasma cell myeloma | Stichting European Myeloma Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05804032 Background | Apr 2023 → Jan 2026 | plasma cell myeloma | University of Heidelberg Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05776940 Comparator | Mar 2023 → Mar 2026 | AL amyloidosis | Air Force Military Medical University, China | Unknown | No outcome recorded |
| Phase 3 | NCT05675319 Comparator | Mar 2023 → Mar 2025 | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded |
| Phase 3 | NCT05681260 Background | Feb 2023 → Dec 2026 expected | T-lymphoblastic lymphoma | Children's Cancer Group, China | Recruiting | No outcome recorded |
| Phase 3 | NCT05623020 Comparator | Nov 2022 → Oct 2030 expected | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05519085 Background | Sep 2022 → Jan 2027 expected | refractory plasma cell neoplasm | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT04975997 Comparator | Jun 2022 → Nov 2027 expected | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06956170 Comparator | Feb 2022 → May 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04973137 Background | Aug 2021 → Apr 2025 | AL amyloidosis | Prothena Biosciences Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04923893 Background | Aug 2021 → Feb 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868667 Background | Jul 2021 → Apr 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06868654 Background | Jul 2021 → Apr 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04939142 Background | Jul 2021 → Dec 2025 overdue | refractory plasma cell neoplasm | Antengene Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04512235 Background | Nov 2020 → Apr 2025 overdue | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04484623 Comparator | Oct 2020 → Jan 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04504825 Background | Aug 2020 → May 2025 overdue | AL amyloidosis | Alexion Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04246047 Background | May 2020 → Oct 2023 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03710603 Background | Dec 2018 → Aug 2023 overdue | plasma cell myeloma | Stichting European Myeloma Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03652064 Background | Nov 2018 → May 2024 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03742297 Comparator | Oct 2018 → Jul 2023 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03617731 Background | Oct 2018 → Jun 2028 expected | plasma cell myeloma | University of Heidelberg Medical Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03319667 Background | Dec 2017 → Apr 2027 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03234972 Background | Nov 2017 → Oct 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03217812 Background | Nov 2017 → Jul 2020 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT03201965 Comparator | Oct 2017 → Feb 2020 | amyloidosis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02755597 Background | Jul 2016 → Mar 2021 | refractory plasma cell neoplasm | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT02541383 Background | Sep 2015 → Aug 2020 | plasma cell myeloma | Intergroupe Francophone du Myelome | Completed | No outcome recorded |
| Phase 3 | NCT02495922 Background | Jun 2015 → Jun 2021 | plasma cell myeloma | University of Heidelberg Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02351427 Comparator | Feb → Dec 2015 | — | Asan Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02195479 Background | Dec 2014 → Nov 2017 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02136134 Background | Aug 2014 → Jan 2016 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01971658 Comparator | Oct 2013 → Aug 2015 | plasma cell myeloma | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01916252 Comparator | Sep 2013 → Nov 2016 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT01818752 Comparator | Jul 2013 → Jul 2016 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01734928 Background | Jan 2013 → May 2022 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01568866 Comparator | Jun 2012 → Nov 2014 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01266811 Background | Jul 2011 → Apr 2014 | plasma cell myeloma | Centocor, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01208818 Background | Jun 2011 → Sep 2015 | chronic renal failure syndrome | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01470131 Background | May 2011 → Jan 2017 | plasma cell myeloma | AB Science | Terminated | No outcome recorded |
| Phase 3 | NCT01208766 Comparator | Jan 2011 → Dec 2020 | plasma cell myeloma | HOVON Foundation | Completed | No outcome recorded |
| Phase 3 | NCT01109004 Comparator | May 2010 → Jan 2017 | plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT01554852 Comparator | May 2010 → Dec 2021 | plasma cell myeloma | University of Leeds | Unknown | No outcome recorded |
| Phase 3 | NCT01023308 Background | Dec 2009 → Jul 2015 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01002248 Background | Dec 2009 → Mar 2013 | plasma cell myeloma | AEterna Zentaris | Terminated | No outcome recorded |
| Phase 3 | NCT03402295 Comparator | Jun 2009 → Jun 2014 | chemotherapy-induced toxicity, plasma cell myeloma | Grupo de Estudos Multicentricos em Onco-Hematologia | Completed | No outcome recorded |
| Phase 3 | NCT00813150 Background | Jan 2009 → Jan 2013 | plasma cell myeloma | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00773747 Background | Dec 2008 → Sep 2011 | plasma cell myeloma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00734877 Comparator | Jul 2008 → Sep 2027 expected | plasma cell myeloma | University of Arkansas | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00910897 Comparator | Mar 2008 → Aug 2009 | plasma cell myeloma | Intergroupe Francophone du Myelome | Unknown | No outcome recorded |
| Phase 3 | NCT00546780 Comparator | Feb 2008 → Mar 2010 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00657553 Comparator | Feb 2008 → Jan 2009 | plasma cell myeloma | University of Arkansas | Terminated | No outcome recorded |
| Phase 3 | NCT01998503 Comparator | Dec 2007 → Jun 2013 | amyloidosis | Nanjing University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00602511 Comparator | Oct 2007 → Sep 2010 | plasma cell myeloma | Nordic Myeloma Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00522392 Background | Sep 2007 → Aug 2012 | plasma cell myeloma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT00507416 Background | Jun 2007 → Mar 2013 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00573391 Background | Aug 2006 → Jul 2008 | plasma cell myeloma | University of Arkansas | Terminated | No outcome recorded |
| Phase 3 | NCT01063179 Comparator | May 2006 → Jul 2014 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | No outcome recorded |
| Phase 3 | NCT00461747 Comparator | Mar 2006 → Dec 2008 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00443235 Background | Mar 2005 → Mar 2007 | plasma cell myeloma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00111748 Comparator | Feb 2005 → Sep 2006 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07334535 Comparator | Jan 2026 → Jul 2028 expected | plasma cell myeloma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07025005 Comparator | Aug 2025 → Jun 2026 overdue | peripheral neuropathy, plasma cell myeloma | Tanta University | Recruiting | No outcome recorded |
| Phase 4 | NCT04612582 Background | Jan 2020 → Jan 2023 | AL amyloidosis | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03416374 Background | Feb 2018 → May 2021 | refractory plasma cell neoplasm | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT02577783 Background | Oct 2015 → Oct 2021 | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 4 | NCT02525172 Background | Aug 2015 → Jul 2020 | glycogen storage disease II | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01868828 Background | May 2013 → May 2015 | plasma cell myeloma | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT03737136 Comparator | Nov 2019 → May 2024 | transplant rejection | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| — | NCT03401372 Background | Apr 2018 → Dec 2020 | AL amyloidosis | Jian Li | Completed | No outcome recorded |
| — | NCT04008888 Background | Jan 2018 → Jan 2020 | chromosome 17p deletion, extramedullary soft tissue plasmacytoma, plasma cell leukemia, plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| — | NCT01350232 Background | Sep 2009 → Aug 2011 | sickle cell-beta zero-thalassemia, sickle cell-hemoglobin c disease syndrome | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02666209 Background | — | plasma cell myeloma | Dana-Farber Cancer Institute | No longer available | No outcome recorded |
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-22 | Regeneron Pharmaceuticals | Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma regeneron.com ↗ |
| 2020-03-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma otsuka.co.jp ↗ |
| 2017-02-28 | Amgen | Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients amgen.com ↗ |
| 2015-12-05 | Amgen | Pivotal Head-To-Head ENDEAVOR Study Results Published in The Lancet Oncology Demonstrate Superiority of Kyprolis® (carfilzomib) Combination Over Velcade® (bortezomib) Combination amgen.com ↗ |
| 2015-03-02 | Amgen | Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma amgen.com ↗ |
| 2014-10-10 | Takeda | FDA Approves VELCADE ® (bortezomib) for Injection for Previously Untreated Patients with Mantle Cell Lymphoma takeda.com ↗ |
| 2014-08-11 | Takeda | FDA Approves VELCADE ® (bortezomib) Retreatment in Patients with Multiple Myeloma takeda.com ↗ |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 969 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bortezomib | “Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin) and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone...” NCT01460602 ↗893“The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab,...” NCT07099391 ↗ “Thirty-three newly diagnosed, symptomatic patients with MM received bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8 and 11, cyclophosphamide 300 mg/m(2) orally on days 1,...” PMID 19225538 ↗ Feb 2009 “The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment...” NCT07709715 ↗ “Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide,...” NCT07149857 ↗ “The purpose of this study is to determine whether Bortezomib is effective in the treatment of patients with non-small-cell lung cancer who have not received any prior...” NCT00346645 ↗ “Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in...” NCT02573935 ↗ “A phase I study was conducted to determine the tolerability and the maximum tolerated dose of bortezomib when administered in combination with IFN-α-2b to patients with...” PMID 24316557 ↗ Jan 2014 “PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma” NCT00319865 ↗ “Bortezomib (VELCADE), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma.” PMID 20012045 ↗ Dec 2009 “Phase II Clinical Study of Daratumumab Combined With Bortezomib, Lenalidomide and Dexamethasone (DVRd) in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma” NCT06158269 ↗ “VELCADE™ (bortezomib) for injection is a small molecule proteasome inhibitor developed by Millennium Pharmaceuticals, Inc., (MPI) as a novel agent to treat human malignancies.” NCT00440076 ↗ “The primary objective is to assess the efficacy and safety of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (Dara-VRD) followed by cilta-cel in high-risk SMM.” NCT06574126 ↗ “This is a phase II (2 parts), open-label, single arm, multicenter study to evaluate the efficacy and safety of nemtabrutinib in combination with bortezomib and rituximab” NCT07464210 ↗ “Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.” PMID 25911554 ↗ Apr 2015 “Lenalidomide, which is also known as Revlimid® and Bortezomib, which is also known as Velcade®, are approved by the FDA for treatment of Multiple Myeloma.” NCT02666209 ↗ “Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care” NCT04973137 ↗ “Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.” NCT06418477 ↗ “A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma” NCT00636792 ↗ “The desensitization regimen consisted of 2 doses of IVIG (2 g/kg), a single dose of rituximab (375 mg/m), and 4 doses of bortezomib (1.3 mg/m).” PMID 26844479 ↗ Feb 2016 “Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients” NCT04025450 ↗ “Bortezomib (Velcade formerly PS 341) is a proteasome inhibitor which has shown promising activity in the treatment of refractory myeloma.” NCT00169468 ↗ “Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9” NCT01672736 ↗ “A new drug (bortezomib [VelcadeTM PS-341]) has been shown in recent studies to be effective in subjects with advanced multiple myeloma.” NCT00573391 ↗ “Pre-clinical studies combining the proteasome inhibitor bortezomib with anthracyclines have shown enhanced anti-tumor activity.” PMID 18327587 ↗ Mar 2008 “Cohort 1: All patients will receive two cycles of induction therapy with standard chemotherapy, Bortezomib and Isatuximab.” NCT06648889 ↗ “Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.” PMID 33478922 ↗ Dec 2020 “VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) versus Velcade (Bortezomib) Cyclophosphamide Dexamethasone (VCD)” NCT01971658 ↗ “liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD)” NCT02858999 ↗ “VTD is a combination of drugs consisting of VelcadeTM (also known as bortezomib), Thalidomide, and Dexamethasone.” NCT00577668 ↗ “Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia” NCT01162031 ↗ “A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma” NCT01114282 ↗ “Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone” NCT05231629 ↗ “Bortezomib is designed to block a protein that causes cells to grow. This may cause cancer cells to die.” NCT01440582 ↗ “Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone” NCT06087653 ↗ “VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma” NCT00085696 ↗ “One of the new active agents in multiple myeloma is VELCADE (bortezomib, formerly known as VELCADE).” NCT00135187 ↗ “One of the new active agents in multiple myeloma is Velcade (bortezomib, formerly known as PS-341).” NCT00116961 ↗ “combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin)” NCT00199212 ↗ “Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)” NCT01852799 ↗ “Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma” NCT00715208 ↗ “Velcade, also known as bortezomib, is injected directly into the vein all at once.” NCT01266811 ↗ “Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment” NCT01084837 ↗ “one 6-weeks cycle of Velcade (Bortezomib) as an intravenous bolus twice weekly” NCT01237249 ↗ “Four 21-day cycles of a combination of bortezomib i.v. (intravenous) 1.3 mg/m2” NCT00872521 ↗ “Bortezomib plus thalidomide and prednisone (VTP; n=130) as induction therapy” PMID 20739218 ↗ Aug 2010 “Bortezomib: 1.3 mg/m2 given subcutaneous (SC) injection on days 1, 8,15, 22” NCT03896737 ↗ “Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide” NCT01160484 ↗ “Cycle 1, 4, 7, etc - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle” NCT00691704 ↗ “treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.” NCT06771180 ↗ “bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle” NCT01277016 ↗ “VRD：Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm” NCT05870917 ↗ “Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion” NCT05470491 ↗ “Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)” NCT04008888 ↗ “Humanized mAb targeting CD47 plus dexamethasone plus bortezomib” NCT04445701 ↗ “Bortezomib (d 1, 8, 15, 22, 1.3mg /m2, subcutaneous injection)” NCT04612582 ↗ “VMP (Velcade [bortezomib], melphalan, and prednisone; D-VMP)” PMID 42085642 ↗ Jul 2026 “Bortezomib (Velcade) is a modified dipeptidyl boronic acid” NCT00374699 ↗ “Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection” NCT06246162 ↗ “subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22)” NCT04991103 ↗ “Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle” NCT00670631 ↗ “Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)” NCT01868828 ↗ “Velcade (bortezomib) plus Eloxatin (oxaliplatin)” NCT00996385 ↗ “proteasome inhibitor (bortezomib or carfilzomib)” NCT02188368 ↗ “Bortezomib and Dexamethasone according to label.” NCT03136653 ↗ “Bortezomib salvage therapy will be administered” NCT01445587 ↗ “Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11” NCT00581919 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05860036 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05850286 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05979363 ↗ “Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11” NCT01370434 ↗ “bortezomib:1.3 mg/m2 IVP over 3-5 sec.” NCT00574236 ↗ “Bortezomib SC 1.5 mg/sqm day 1, day 4” NCT01805557 ↗ “Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11” NCT03908138 ↗ “VELCADE (Bortezomib) for Injection” NCT00117351 ↗ “Bexarotene Bortezomib Bosutinib” NCT02551718 ↗ “Bleomycin, Bortezomib, Busulfan” NCT02788201 ↗ “Velcade (PS-341, Bortezomib)” NCT01132911 ↗ “Bortezomib(V）:1.3 mg/m2” NCT06409702 ↗ “Velcade™ (bortezomib)” NCT00136565 ↗ “Velcade® (Bortezomib)” NCT00388635 ↗ “Velcade (Bortezomib)” NCT00469209 ↗ “Velcade (bortezomib)” NCT03234972 ↗ “Velcade (bortezomib)” NCT00734877 ↗ “PS-341 (Bortezomib)” NCT00059618 ↗ “Bortezomib(VELCADE)” NCT00509379 ↗ “Drug: Bortezomib” NCT01315873 ↗ “Drug: Bortezomib” NCT03004287 ↗ “Drug: Bortezomib” NCT03763370 ↗ “Bortezomib” NCT01672736 ↗ “Bortezomib” NCT04817956 ↗ |
| Known as | -Velcade, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00740415 ↗ |
| Known as | Autologous Hematopoietic Stem Cell Transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05063513 ↗ |
| Known as | Bortezomib (PS-341) | “Bortezomib (PS-341)” NCT03016988 ↗ |
| Known as | Bortezomib (velcade) | “Bortezomib (Velcade ®)” NCT01860170 ↗9“Bortézomib (VELCADE®)” NCT01191060 ↗ “Bortezomib (VELCADE®)” NCT01206205 ↗ “Bortezomib (velcade)” NCT01720875 ↗ “bortezomib (Velcade)” NCT00837174 ↗ “Bortezomib (Velcade)” NCT00691704 ↗ “Bortezomib (Velcade)” NCT00250926 ↗ “bortezomib (velcade)” NCT00580320 ↗ “Bortezomib: Velcade” NCT01449344 ↗ “Bortezomib=Velcade” NCT00516191 ↗ |
| Known as | Bortezomib accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | Bortezomib fresenius kabi | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | Bortezomib hospira | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | Bortezomib hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | Bortezomib Injection | “Bortezomib Injection, a kind of chemotherapy drug” NCT06572813 ↗ |
| Known as | Bortezomib or Velcade | “Bortezomib or Velcade” NCT00793650 ↗ |
| Known as | Bortezomib sun | ChEMBL registry synonym — accepted as the source's own label CHEMBL325041 ↗ |
| Known as | bortizomib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02577783 ↗ |
| Known as | Botezomib | “Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability” NCT00257114 ↗ |
| Known as | BTZ | “We previously reported that administration of bortezomib (BTZ) after 4 days of granulocyte colony-stimulating factor (G-CSF) significantly augments mobilization in mice.” PMID 31358485 ↗ May 20194“BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).” NCT02188368 ↗ “Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) \& treatment phase 2 (42 days).” NCT02290431 ↗ “pretreatment with bortezomib (BTZ) 48 hours prior to TMZ to deplete MGMT levels would be safe and tolerated” PMID 32578964 ↗ Jun 2020 “DARA in combination with bortezomib (BTZ) and low-dose dex (DVd)” NCT03651128 ↗ |
| Known as | JNJ-26866138 | “A Phase I/II Study of JNJ-26866138 (Bortezomib) in Japanese Patients With Relapsed or Refractory Multiple Myeloma” NCT00752518 ↗ |
| Known as | LDP-341 | “VELCADE™ (bortezomib) for Injection, formerly known as MLN341, LDP-341 and PS-341.” NCT00063726 ↗ |
| Known as | MLN341 | “VELCADE™ (bortezomib) for Injection, formerly known as MLN341, LDP-341 and PS-341.” NCT00063726 ↗ |
| Known as | NSC 681239 | “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗4“A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide And Low Dose...” NCT00644228 ↗ “Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms” NCT00082784 ↗ “Phase I Trial of Bortezomib (NSC 681239, IND#58443) and Carboplatin in Recurrent or Progressive Epithelial Ovarian Cancer or Primary Peritoneal Cancer” NCT00028912 ↗ “A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer” NCT00028639 ↗ |
| Known as | PS-341 | “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗46“BACKGROUND: Based on evidence of activity in epithelial tumors in preclinical and Phase I studies, its novel mechanism of action, and its tolerability we undertook a study of...” PMID 16983508 ↗ Sep 2006 “The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered...” NCT00200382 ↗ “Bortezomib (PS-341, Velcade ), a proteasome inhibitor, has been reported to have several putative mechanisms of action and it is likely that its toxicity is mediated by...” NCT00923247 ↗ “Bortezomib (also called Velcade or PS-341) has been approved by the US Food and Drug Administration (FDA) for the treatment of myeloma, but has not been approved for the...” NCT00184015 ↗ “A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute...” NCT00382954 ↗ “PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma” NCT00319865 ↗ “Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not exceeding 3.0 mg (equivalent to 1.75 mg/m2), repeated on D1 and D4 every other week.” PMID 16135477 ↗ Sep 2005 “Two new drugs BORTEZOMIB (Velcade®, PS-341) and REVLIMID (CC-5013) have been shown in recent studies to be effective in patients with advanced multiple myeloma.” NCT00093028 ↗ “Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms” NCT00082784 ↗ “A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.” PMID 20574790 ↗ Jun 2010 “A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer” NCT00193232 ↗ “A Phase II Study of the Combination Bortezomib (Velcade, PS-341), Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia” NCT00250926 ↗ “Bortezomib (Velcade formerly PS 341) is a proteasome inhibitor which has shown promising activity in the treatment of refractory myeloma.” NCT00169468 ↗ “Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features” NCT00118144 ↗ “Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).” PMID 17409985 ↗ Nov 2006 “A new drug (bortezomib [VelcadeTM PS-341]) has been shown in recent studies to be effective in subjects with advanced multiple myeloma.” NCT00573391 ↗ “To evaluate the response rate to PS-341 (bortezomib) induction in patients with high risk, newly diagnosed multiple myeloma.” NCT00075881 ↗ “A Phase 1 Study of PXD101 in Combination With Bortezomib (PS-341) in Patients With Advanced Solid Tumors and Lymphoma” NCT00348985 ↗ “A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer” NCT00028639 ↗ “PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma” NCT00048230 ↗ “The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with Docetaxel (Taxotere)” NCT00064610 ↗ “One of the new active agents in multiple myeloma is Velcade (bortezomib, formerly known as PS-341).” NCT00116961 ↗ “A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma” NCT00082966 ↗ “Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia” NCT00511069 ↗ “VELCADE™ (bortezomib) for Injection, formerly known as MLN341, LDP-341 and PS-341.” NCT00063726 ↗ “PAD combination (Ps-341/Bortezomib, Adriamycin, and Dexamethasone)” NCT01370434 ↗ “VELCADE™ (bortezomib) for Injection (formerly PS-341)” NCT00051974 ↗ “VELCADE TM (bortezomib) for Injection, or PS-341” NCT00051987 ↗ “VELCADE TM (bortezomib) for Injection, or PS-341” NCT00064636 ↗ “bortezomib (also known as "Velcade"or PS341)” NCT00441168 ↗ “bortezomib (VELCADE, formerly PS-341)” NCT00504751 ↗ “Bortezomib (VELCADE, PS-341)” NCT00832234 ↗ “Bortezomib (Velcade, PS-341)” NCT01445405 ↗ “Velcade (PS-341, Bortezomib)” NCT01132911 ↗ “Bortezomib (PS-341)” NCT00059631 ↗ |
| Known as | Velcade | “A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or...” NCT00515138 ↗147“The primary objective of this research study is to determine the maximum tolerated dose (MTD) of Ruxolitinib (Jakafi) in combination with standard dose Bortezomib (Velcade) in...” NCT02613598 ↗ “The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the...” NCT01063907 ↗ “Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma...” NCT00389701 ↗ “Subjects are invited to participate in this study that will examine the use of three drugs called Sorafenib (Nexavar), Vorinostat (Zolinza) and Bortezomib (Velcade) for...” NCT01534260 ↗ “The purpose of this study is to allow patients to receive VELCADE™ (bortezomib) for Injection who experienced progressive disease(PD) while receiving high-dose dexamethasone...” NCT00063726 ↗ “Bortezomib (also called Velcade or PS-341) has been approved by the US Food and Drug Administration (FDA) for the treatment of myeloma, but has not been approved for the...” NCT00184015 ↗ “A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute...” NCT00382954 ↗ “MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative...” NCT00564200 ↗ “PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma” NCT00319865 ↗ “A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (Velcade) in Patients With Multiple Myeloma in First or Second Relapse.” NCT01910987 ↗ “Bortezomib (VELCADE), thalidomide and dexamethasone (VTD), as well as melphalan, prednisolone, and thalidomide (MPT) therapy, are highly effective in patients with multiple myeloma.” PMID 20012045 ↗ Dec 2009 “Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme” NCT00998010 ↗ “Phase II Trial of Combination Weekly Bortezomib (VELCADE) and Docetaxel (TAXOTERE) in Patients With Recurrent and/ or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)” NCT00425750 ↗ “A Phase II, Open-Label Trial of Bortezomib (VELCADE®) in Combination With Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer” NCT01633645 ↗ “maintenance treatment with VELCADE (bortezomib) in patients with multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT.” NCT00311337 ↗ “Two new drugs BORTEZOMIB (Velcade®, PS-341) and REVLIMID (CC-5013) have been shown in recent studies to be effective in patients with advanced multiple myeloma.” NCT00093028 ↗ “The purpose of this study is to characterize the clinical pharmacokinetic and pharmacodynamic profiles of the 2 doses of VELCADE (bortezomib) for Injection.” NCT00080405 ↗ “The aim of this pilot study is to investigate the application of proteasome inhibitor Bortezomib (Velcade®, approved for therapy of multiple myeloma)” NCT02102594 ↗ “A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer” NCT00193232 ↗ “Bortezomib (Velcade®) is the first generation proteasome inhibitor developed by Millennium Pharmaceuticals, Inc. as an anti-cancer medication.” NCT06853080 ↗ “Bortezomib (VELCADE) 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.” NCT00103506 ↗ “Bortezomib (Velcade formerly PS 341) is a proteasome inhibitor which has shown promising activity in the treatment of refractory myeloma.” NCT00169468 ↗ “VELCADE™ (bortezomib) for Injection is a small molecule proteasome inhibitor developed by Millennium Pharmaceuticals, Inc.” NCT01242267 ↗ “Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma” NCT00148018 ↗ “Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia” NCT01162031 ↗ “Bortezomib (Velcade) 1.3 milligram per square meter (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8, and 11;” NCT01539083 ↗ “PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma” NCT00048230 ↗ “Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma” NCT00334932 ↗ “Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma” NCT01376401 ↗ “doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)” NCT02577783 ↗ “VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma” NCT00085696 ↗ “One of the new active agents in multiple myeloma is Velcade (bortezomib, formerly known as PS-341).” NCT00116961 ↗ “bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles” NCT01286077 ↗ “combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin)” NCT00199212 ↗ “Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma” NCT00262860 ↗ “Phase I Trial of Bortezomib (VELCADE™) and Celecoxib in Patients With Advanced Solid Tumors” NCT00290680 ↗ “Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma” NCT00193557 ↗ “Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia” NCT00511069 ↗ “phase II data with the proteasome inhibitor bortezomib (Velcade®) has been heartening” NCT00985907 ↗ “Combination Therapy With Velcade (Bortezomib), Doxorubicin, and Dexamethasone (PAD)” NCT00814541 ↗ “Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma” NCT00715208 ↗ “Tarceva™ (Erlotinib) Alone and of Tarceva Plus VELCADE* (Bortezomib) for Injection” NCT00283634 ↗ “bortezomib (velcade), lenalidomide (revlimid), and dexamethasone (VRd) regimen” NCT07025005 ↗ “Velcade IV twice a week for two weeks on Days 1, 4, 8 and 11 of each cycle.” NCT00276614 ↗ “in combination with bortezomib (Velcade®) in patients with Multiple Myeloma” NCT00352742 ↗ “the active ingredient in the study drug Velcade (bortezomib)” NCT00129207 ↗ “Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)” NCT02541383 ↗ “Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11” NCT01206205 ↗ “Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen” NCT00799539 ↗ “VELCADE™ (bortezomib) for Injection (formerly PS-341)” NCT00051974 ↗ “VELCADE TM (bortezomib) for Injection, or PS-341” NCT00051987 ↗ “Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11” NCT01457144 ↗ “Ibrutinib (Imbruvica®), Bortezomib (Velcade®)” NCT03129828 ↗ “bortezomib (also known as "Velcade"or PS341)” NCT00441168 ↗ “VELCADE [Bortezomib] and Dexamethasone” NCT00561743 ↗ “bortezomib (VELCADE, formerly PS-341)” NCT00504751 ↗ “VELCADE TM (bortezomib) for Injection” NCT00063713 ↗ “VELCADE TM (bortezomib) for Injection” NCT00064610 ↗ “VELCADE (bortezomib) for injection” NCT00111319 ↗ “Bortezomib (Velcade, PS-341)” NCT01445405 ↗ “Drug: bortezomib (Velcade ®)” NCT01916252 ↗ “Bortezomib (Velcade®)” NCT01103778 ↗ “Bortezomib (Velcade®)” NCT06918002 ↗ “Velcade (Bortezomib)” NCT00770731 ↗ “Bortezomib (Velcade)” NCT00636311 ↗ “VELCADE (bortezomib)” NCT00531453 ↗ “Velcade (Bortezomib)” NCT00256776 ↗ “VELCADE (bortezomib)” NCT00507442 ↗ “Velcade (bortezomib)” NCT00329589 ↗ “Bortezomib (Velcade)” NCT00373906 ↗ “Bortezomib (Velcade)” NCT00142129 ↗ “Bortezomib (Velcade)” NCT00369226 ↗ “bortezomib (Velcade)” NCT01158105 ↗ “Bortezomib (Velcade)” NCT01062230 ↗ “PS-341 (VELCADE)” NCT00512798 ↗ |
| Known as | Velcade (bortezomib) | “Velcade (bortezomib)” NCT01554852 ↗3“Velcade (Bortezomib)” NCT02237261 ↗ “Velcade (bortezomib)” NCT00516100 ↗ “Velcade : Bortezomib” NCT01045681 ↗ |
| Known as | Velcade TM | “Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in...” NCT01386398 ↗6“VTD is a combination of drugs consisting of VelcadeTM (also known as bortezomib), Thalidomide, and Dexamethasone.” NCT00577668 ↗ “Bortezomib, or Velcade(TM), is given for a few seconds by a rapid push through a needle into the vein.” NCT00092222 ↗ “VELCADE TM (bortezomib) for Injection, or PS-341” NCT00051987 ↗ “VELCADE TM (bortezomib) for Injection, or PS-341” NCT00064636 ↗ “VELCADE TM (bortezomib) for Injection” NCT00063713 ↗ “VELCADE TM (bortezomib) for Injection” NCT00064610 ↗ |
| Known as | Velcade(R) | “Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles” NCT00777738 ↗ |
| Known as | Velcade-drug | “PS-341 (Velcade-drug)” NCT00200382 ↗ |
| Action | Inhibit | “Proteasome inhibition with bortezomib (PS-341)” PMID 16135477 ↗ Sep 2005 |
| Modality | Small molecule | “Bortezomib (Velcade) is a modified dipeptidyl boronic acid” NCT00374699 ↗ |
| Route | Intravenous | “Patients receive PS-341 IV on days 1 and 4.” NCT00004002 ↗ |
| Target | TGFB1 | “Bortezomib, an FDA approved proteasomal inhibitor inhibits TGF-b1 signaling” NCT01163786 ↗ |